New data, presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting, has demonstrated that Tremfya (guselkumab) provides long-term skin clearance in patients with moderate to severe plaque psoriasis.
Psoriasis
Guselkumab is a self-injectable treatment available throughout Europe from Janssen Pharmaceutical Companies of Johnson & Johnson. It works by selectively targeting IL-23, a key driver of the immune inflammatory response in psoriasis.
“The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for moderate to severe plaque psoriasis, and as an option for patients who have been withdrawn from therapy and retreated,” said study investigator Prof. Kristian Reich, MD of Dermatologikum Berlin and SCIderm Research Institute in Hamburg, Germany. “These data provide important information to dermatologists should they need to interrupt treatment with guselkumab for a period of time, as the findings demonstrate guselkumab quickly and robustly re-established a PASI 90 response within six months.”
The VOYAGE 2 trial demonstrated that the majority of patients receiving treatment with Tremfya achieved a significant improvement in their condition at week 28 and maintained that through to week 72 if treatment was continued.